Novartis may have the most new drug approvals, but Roche, Lilly and AbbVie's launches win on value: report

Roche, Eli Lilly and AbbVie seem to be getting the most out of their new launches, thanks to the advent of new and upcoming blockbusters like Roche and Lilly’s respective cancer drugs Tecentriq and Verzenio, plus AbbVie’s autoimmune up-and-comers Rinvoq and Skyrizi, Evaluate said.